We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cynvenio, Cure Forward Partner
News

Cynvenio, Cure Forward Partner

Cynvenio, Cure Forward Partner
News

Cynvenio, Cure Forward Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cynvenio, Cure Forward Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The partnership will leverage Cynvenio's ClearID liquid biopsy test, which detects tumor cells from blood samples. The test aids clinicians in choosing optimal therapies for their patients and can accelerate patient enrollment in clinical trials. 

Patients enrolled in Cure Forward and tested with ClearID will have direct access to their data. The test must be ordered by a physician. 

"The barriers to personalized medicine are too high for too many patients," Cure Forward CEO Martin Naley said in a statement. "We help people find innovative testing options like the ClearID test from Cynvenio and then use those results to be more effective champions of their own care." 

Cure Forward is newly formed and also forged a partnership with Paradigm.

Cynvenio announced on Wednesday it raised $25.5 million in a Series B financing round.

Advertisement